Difficulties and Errors in Diagnosis of Breast Neoplasms

Giess, Catherine S.; Frost, Elisabeth; Birdwell, Robyn L.

doi:10.1053/j.sult.2012.01.007

Cited by 34 publications

(24 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BREAST IMAGING: Developing Asymmetry at Mammography Chesebro et al Errors in interpretation and management of different types of asymmetries have been reviewed (15). Authors of published studies (16-21) on missed breast cancers found that many were focal asymmetries or asymmetries, presumably developing, although the term developing asymmetry had not yet been introduced into clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Developing Asymmetry at Mammography: Correlation with US and MR Imaging and Histopathologic Findings

Chesebro¹,

Winkler²,

Birdwell³

et al. 2016

Radiology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Developing Asymmetry at Mammography: Correlation with US and MR Imaging and Histopathologic Findings

Chesebro¹,

Winkler²,

Birdwell³

et al. 2016

Radiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The majority of diagnostic delays in our study resulted from erroneous BI-RADS assessments (57.3%) and false-negative biopsy results (32.3%). Diagnostic delays due to erroneous mammographic assessments are not uncommon, lesions can be missed, misinterpreted or overlooked (Ganry et al , 2004; Ciatto et al , 2007; Giess et al , 2012). Also false-negative biopsy results are known as probable causes of diagnostic delays (Youk et al , 2007).…”

Section: Discussionmentioning

confidence: 99%

Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands

et al. 2013

View full text Add to dashboard Cite

Background:Diagnostic surgical breast biopsies have several disadvantages, therefore, they should be used with hesitation. We determined time trends in types of breast biopsies for the workup of abnormalities detected at screening mammography. We also examined diagnostic delays.Methods:In a Dutch breast cancer screening region 6230 women were referred for an abnormal screening mammogram between 1 January 1997 and 1 January 2011. During two year follow-up clinical data, breast imaging-, biopsy-, surgery- and pathology-reports were collected of these women. Furthermore, breast cancers diagnosed >3 months after referral (delays) were examined, this included review of mammograms and pathology specimens to determine the cause of the delays.Results:In 41.1% (1997–1998) and in 44.8% (2009–2010) of referred women imaging was sufficient for making the diagnosis (P<0.0001). Fine-needle aspiration cytology decreased from 12.7% (1997–1998) to 4.7% (2009–2010) (P<0.0001), percutaneous core-needle biopsies (CBs) increased from 8.0 to 49.1% (P<0.0001) and surgical biopsies decreased from 37.8 to 1.4% (P<0.0001). Delays in breast cancer diagnosis decreased from 6.7 to 1.8% (P=0.003).Conclusion:The use of diagnostic surgical breast biopsies has decreased substantially. They have mostly been replaced by percutaneous CBs and this replacement did not result in an increase of diagnostic delays.

show abstract

“…To probe biodistribution of nanoprobes, the 99m Tc‐USPIO‐C595 was administered to normal female Balb/c. A 50 µl aliquot of solution of 99m Tc‐USPIO‐C595 containing 100 µg Fe and 7–7.4 MBq radioactivity was intravenously injected into the mice, through the tail vein . Five mice were sacrificed in a CO 2 chamber at each time interval (1, 2.5, 5, 15, 30 and 60 min and 2, 6, 18, 24 and 48 h post injection).…”

Section: Experimental Methodsmentioning

confidence: 99%

Monoclonal antibody conjugated magnetic nanoparticles could target MUC‐1‐positive cells in vitro but not in vivo

Shanehsazzadeh

Gruettner²,

Lahooti

et al. 2014

Contrast Media & Molecular

View full text Add to dashboard Cite

MUC1 antigen is recognized as a high-molecular-weight glycoprotein that is unexpectedly over-expressed in human breast and other carcinomas. In contrast, C595 a monoclonal antibody (mAb) against the protein core of the human urinary epithelial machine, is commonly expressed in breast carcinomas. The aim of this study was to conjugate ultra-small super paramagnetic iron oxide nanoparticles (USPIO) with C595 mAb, in order to detect in vivo MUC1 expression. A dual contrast agent (the C595 antibody-conjugated USPIO labeled with 99mTc) was prepared for targeted imaging and therapy of anti-MUC1-expressing cancers. The C595 antibody-conjugated USPIO had good stability and reactivity in the presence of blood plasma at 37 °C. No significant differences were observed in immunoreactivity results between conjugated and nonconjugated nanoparticles. The T1 and T2 measurements show >79 and 29% increments (for 0.02 mg/ml iron concentrations) in T1 and T2 values for USPIO-C595 in comparison with USPIO, respectively. The nanoprobes showed the interesting targeting capability of finding the MUC1-positive cell line in vitro. However, we found disappointing in vivo results (i.e. very low accumulation of nanoprobes in the targeted site while >80% of the injected dose per gram was taken up by the liver and spleen), not only due to the coverage of targeting site by protein corona but also because of absorption of opsonin-based proteins at the surface of nanoprobes.

show abstract

Difficulties and Errors in Diagnosis of Breast Neoplasms

Cited by 34 publications

References 58 publications

Developing Asymmetry at Mammography: Correlation with US and MR Imaging and Histopathologic Findings

Developing Asymmetry at Mammography: Correlation with US and MR Imaging and Histopathologic Findings

Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands

Monoclonal antibody conjugated magnetic nanoparticles could target MUC‐1‐positive cells in vitro but not in vivo

Contact Info

Product

Resources

About